Congratulations CANet Network Investigators! • Cardiovascular Network of Canada — CANet

Congratulations CANet Network Investigators!

We are happy to announce that 2 of the 3 CANet-supported projects have successfully received funding from the Accelerating Clinical Trials Canada Consortium (ACT).

ACT consists of hundreds of investigators, stakeholders, and highly qualified research personnel from 11 trial units and 28 research networks across Canada. The central guiding principle of the ACT Consortium is that its activities will accelerate, optimize, and facilitate the conduct, implementation, and results translation from high-quality, high-impact randomized controlled trials (RCTs) to improve health in Canada and around the world.

They were among 11 funded projects from 43 high-quality applications submitted in the Request For Application (RFA #1 — Supporting the Completion of High-Impact Randomized Controlled Trials).

Congratulations to the research teams, investigators and staff involved with these 2 projects.

CANet Derek REFINE ICD (Risk Estimation Following Infarction Noninvasive Evaluation – ICD efficacy) is a multi-centre randomized controlled trial.
Dr. Derek Exner
Libin Cardiovascular Institute

CANet Ian StiellRAFF4: A Randomized Trial of Anti-Arrhythmic Agents to Improve Management of Emergency Department Patients with Acute Atrial Fibrillation.
Dr. Ian Stiell
Ottawa Hospital Research Institute

Other successful applications for the RFA #1 are:

REVISE: Re-Evaluating the Inhibition of Stress Erosions in the ICU Trial.
Dr. Deborah Cook

ARTESIA: Trial Apixaban for the Reduction of Thrombo-Embolism in Patients with Device-Detected Sub-Clinical Atrial Fibrillation.
Dr. Jeff Healey 

CYCLE: Critical Care Cycling to Improve Lower Extremity Strength.
Dr. Michelle Kho 

HEMOTION: HEMOglobin transfusion threshold in Traumatic brain Injury Optimization.
Dr. Alexis F Turgeon

ACHIEVE: Aldosterone bloCkade for Health Improvement EValuation in End-stage renal disease (ACHIEVE) trial.
Dr. Michael Walsh

CLEAR: A 2×2 factorial placebo-controlled trial of colchicine and spironolactone in patients with acute myocardial infarction (MI).
Dr. Sanjit Jolly  

COP-AF: Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery.
Dr. David Conen  

EnAKT (Effect of a Multi-Component Quality Improvement Intervention on Patient Access to Kidney Transplantation and Living Kidney Donation: The EnAKT LKD Randomized Clinical Trial.
Dr. Amit Garg  

B-Free: Benzodiazepine-free cardiac anesthesia for reduction of postoperative delirium.
Dr. Jessica Spence

ACT Call for Proposals

RFA #2 — Advances in the Conduct of Randomized Controlled Trials

CANet received 3 applications in total. We will support all 3 for this RFA.

Applications for the next RFA #3 — Evaluate Canadian Biotechnologies with Randomized Controlled Trials due June 19, 2023. Details below:

RFA #3 — Evaluate Canadian Biotechnologies with Randomized Controlled Trials

A total of $2.0 million is available for this RFA. The maximum requested budget for any application is $400,000. Although the funding available may not be sufficient for a full-scale study, phase 2 and pilot or Vanguard trials to assess, for example, safety, recruitment potential, and feasibility are welcome.

To learn more, click here.